Page 21 - CIBERES-2015-eng

Pulmonary Fibrosis
COORDINATOR: DR . MARÍA MOLINA
In 2015 the Pulmonary Fibrosis Programme com- pleted the corporate research programme enti- tled “Cell plasticity and microenvironment in lung fibrosis: looking for its regulation as a potential treatment”. The most significant achievements involved were:
TRANSFER AND INNOVATION:
a) Utility model (V. Vicens et al),
b)Patent applied for: PCT application number PCT/EP2015/050325.
CIBERES-IDIBELL+CIBERBBN-UAB.
c)Work in cooperation with biotech company
Scientific Programmes
17 “PEER REVIEWED” PUBLICATIONS GENERATED, HIGHLIGHTING THE FOLLOWING:
• V. Vicens et al. Resp. Research. Fibroblasts viability and phenotype changes into glycated stiffened three dimensional collagen matrices. 2015;16:82, which establishes a new model of three-dimensional in vitro pro-fibrotic culture which comes closer to human tissue complex- ity in the study of pulmonary fibrosis.
• Milara J, et al. Roflumilast prevents the meta- bolic effects of bleomycin-induced fibrosis in a murin model. PLoS One. 2015;10:e0133453, where the preventive effects of pulmonary damage achieved with roflumilast are deter- mined.
• Bonella F, et al. European IPF Patient Charter: unmet needs and a call to action for health- care policymakers. Eur Respir J. ERJ-01204- 2015. In press, which stipulates minimum healthcare, therapeutic and research levels to be obtained in IPF in the European framework of Rare Diseases.
Advanced Medical Project (AMP, Antonio Moli- na) for transfer, through which outside financ- ing has been obtained to carry out part of the studies included in the corporate project and in future proposals (2016-2018).
STRENGTHENING INTERCIBER RELATIONS: CIBERES-CIBERER-CIBERBBN. As a result of this the 2nd CIBERES-CIBERER Workshop was held on Telomeric Regulation in IPF. Hospitalet de Llo- bregat (Barcelona), 4th December 2015.
INTERNATIONALISATION: application for Start- ing Grant from CIBERES, ERC 2015-2016, partici- pation in the strategic international forum on rare diseases for IPF (Bonella F, et al), along with the IPF relatives and patients’ association (AFEFPI).
IPF COHORT: telomere shortening and its regula- tion. In December 2015 financing was obtained for development of the IPF cohort, collecting samples to be biobanked at the CIBERES Biobank Platform. This is the first cohort of these charac- teristics for this rare respiratory disease nation- wide and one of the few held abroad.
CIBERES I Annual report 2015 I 21